PS2 supporting (one proven de novo occurrence), PS3 strong (well‐established functional studies supportive of a damaging effect), PS4 supporting (one proband meeting FPD‐MM phenotype), PM1 moderate (located in mutational hotspot), PM2 (absent from controls), PP3 supporting (computational evidence supports deleterious effect). This evidence concerns the gene TAS2R6P and Miyoshi myopathy.